• Michel van Kruchten, Elisabeth G E de Vries, Myles Brown, Erik F J de Vries, Andor W J M Glaudemans, Rudi A J O Dierckx, Carolien P Schröder, and Geke A P Hospers.
• Department of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
• Lancet Oncol.. 2013 Oct 1;14(11):e465-75.

AbstractOestrogen receptors are overexpressed in around 70% of all breast cancers, and are a target for endocrine therapy. These receptors can be visualised on PET with use of 16α-[(18)F]-fluoro-17β-oestradiol ((18)F-FES) as a tracer. Compared with biopsy, which enables assessment of individual sites, whole-body (18)F-FES-PET enables quantification of oestrogen-receptor expression in all metastases. In several studies, measurement of tumour protein expression in oestrogen receptors by (18)F-FES-PET, concurrent with biopsy, detected oestrogen-receptor-positive tumour lesions with a sensitivity of 84% and specificity of 98%. Roughly 45% of patients with metastatic breast cancer have discordant oestrogen-receptor expression across lesions (ie, (18)F-FES-positive and (18)F-FES-negative metastases). Low tumour (18)F-FES uptake in metastases can predict failure of hormonal therapy in patients with oestrogen-receptor-positive primary tumours. Finally, (18)F-FES-PET has shown that oestrogen-receptor binding capacity changes after intervention with hormonal drugs, but findings need to be confirmed. Factors other than oestrogen-receptor expression, including menopausal status and concomitant therapies, that can affect tumour (18)F-FES uptake must be taken into account.Copyright © 2013 Elsevier Ltd. All rights reserved.

10 keywords...

hide…